Literature DB >> 12374432

The Wnt signaling pathway in bipolar disorder.

Todd D Gould, Husseini K Manji.   

Abstract

The Wnt signaling pathway is a highly conserved pathway critical for proper embryonic development. However, recent evidence suggests that this pathway and one of its key enzymes, glycogen synthase kinase 3beta, may play important roles in regulating synaptic plasticity, cell survival, and circadian rhythms in the mature CNS-all of which have been implicated in the pathophysiology and treatment of bipolar disorder. Furthermore, two structurally highly dissimilar medications used to treat bipolar disorder, lithium and valproic acid, exert effects on components of the Wnt signaling pathway. Together, these data suggest that the Wnt signaling pathway may play an important role in the treatment of bipolar disorder. Here, the authors review the modulation of the Wnt/GSK-3beta signaling pathway by mood-stabilizing agents, focusing on two therapeutically relevant aspects: neuroprotection and modulation of circadian rhythms. The future development of selective GSK-3beta inhibitors may have considerable utility not only for the treatment of bipolar disorder but also for a variety of classical neurodegenerative disorders.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12374432     DOI: 10.1177/107385802237176

Source DB:  PubMed          Journal:  Neuroscientist        ISSN: 1073-8584            Impact factor:   7.519


  67 in total

Review 1.  GSK-3: tricks of the trade for a multi-tasking kinase.

Authors:  Bradley W Doble; James R Woodgett
Journal:  J Cell Sci       Date:  2003-04-01       Impact factor: 5.285

Review 2.  Diseases of Wnt signaling.

Authors:  Mark L Johnson; Nalini Rajamannan
Journal:  Rev Endocr Metab Disord       Date:  2006-06       Impact factor: 6.514

3.  The underlying neurobiology of bipolar disorder.

Authors:  Husseini K Manji; Jorge A Quiroz; Jennifer L Payne; Jaskaran Singh; Barbara P Lopes; Jenilee S Viegas; Carlos A Zarate
Journal:  World Psychiatry       Date:  2003-10       Impact factor: 49.548

4.  Developmental exposure to valproic acid alters the expression of microRNAs involved in neurodevelopment in zebrafish.

Authors:  Neelakanteswar Aluru; Kristina L Deak; Matthew J Jenny; Mark E Hahn
Journal:  Neurotoxicol Teratol       Date:  2013-10-12       Impact factor: 3.763

5.  Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy.

Authors:  Zhong Wang; Kevin S Smith; Mark Murphy; Obdulio Piloto; Tim C P Somervaille; Michael L Cleary
Journal:  Nature       Date:  2008-09-17       Impact factor: 49.962

6.  Identification of a glycogen synthase kinase-3β inhibitor that attenuates hyperactivity in CLOCK mutant mice.

Authors:  Alan P Kozikowski; Hendra Gunosewoyo; Songpo Guo; Irina N Gaisina; Richard L Walter; Ariel Ketcherside; Colleen A McClung; Andrew D Mesecar; Barbara Caldarone
Journal:  ChemMedChem       Date:  2011-07-05       Impact factor: 3.466

7.  Does gene deletion of AMPA GluA1 phenocopy features of schizoaffective disorder?

Authors:  Paul J Fitzgerald; Chris Barkus; Michael Feyder; Lisa M Wiedholz; Yi-Chyan Chen; Rose-Marie Karlsson; Rodrigo Machado-Vieira; Carolyn Graybeal; Trevor Sharp; Carlos Zarate; Judith Harvey-White; Jing Du; Rolf Sprengel; Peter Gass; David Bannerman; Andrew Holmes
Journal:  Neurobiol Dis       Date:  2010-08-08       Impact factor: 5.996

8.  Bone morphogenetic protein 4 stimulates neuronal differentiation of neuronal stem cells through the ERK pathway.

Authors:  Byoung-San Moon; Ju-Yong Yoon; Mi-Yeon Kim; Sang-Hun Lee; Thomas Choi; Kang-Yell Choi
Journal:  Exp Mol Med       Date:  2009-02-28       Impact factor: 8.718

9.  GSK-3β polymorphism discriminates bipolar disorder and schizophrenia: a systematic meta-analysis.

Authors:  Hui Tang; Na Shen; Huijuan Jin; Dan Liu; Xiaoping Miao; Ling-Qiang Zhu
Journal:  Mol Neurobiol       Date:  2013-02-27       Impact factor: 5.590

10.  GSK3beta regulates differentiation and growth arrest in glioblastoma.

Authors:  Serdar Korur; Roland M Huber; Balasubramanian Sivasankaran; Michael Petrich; Pier Morin; Brian A Hemmings; Adrian Merlo; Maria Maddalena Lino
Journal:  PLoS One       Date:  2009-10-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.